Core One Labs WKN: A3CSSU ISIN: CA21872J3073 Kürzel: LD6 Forum: Aktien Thema: Hauptdiskussion

Geht seit Jahren abwärts und mindestens schon zwei RS

Was machen die? Ich will investieren

Eins zum Wochenanfang alle mal freundlich sein wir wollen doch das gleiche außer die , die ....

😂😂😂😂

Bis zum Abend

Heute 60cent drin

Boah so viele hier die nicht investiert sind 🤔

Finger weg sage ich euch auch! Macht euch schlau zum CEO und wo der schon war. Das sind alles Fake Firmen wo der war

Vorsicht!!! Nur Pushernews hier! Finger weg!!

Bankrott das Ding

Na dann lass dich überraschen

Sind die Nachrichten auf der Homepage nichts wert ? Das sehe ich doch anders

Ja, die haben alle eines gemeinsam, lange Gesichter

Typische Polli.....trigger Meldung

...d i e Chance zum günstigen Einstieg !

Vancouver, British Columbia, Canada – May 5, 2022 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) is pleased to announce that it is in discussions with several pharmaceutical laboratories and research organizations to supply them with active pharmaceutical ingredient (API) psilocybin to meet their psychedelic research needs. Scientific interest in psilocybin has grown exponentially in recent years, with many high profile clinical trials showing enormous potential for the psychedelic compound in treating various mental health and neurological disorders, such as anxiety, depression, obsessive-compulsive disorder, various addictions, as well as Alzheimer’s and Parkinson’s diseases, to name a few[1]. Promising results from many of these trials, though still in early stages and requiring further study[2], have given rise to rapid growth of a psychedelic industry and the emergence of many public and private entities engaged in research with psychedelics intended for medical use. With the psychedelics industry still in its infancy, Core One has been taking significant steps to position itself as a leading full-cycle psychedelics supply chain solution. The Company has the potential to produce its own psychedelic compounds at a Good Manufacturing Practices (“GMP”) facility, while, in collaboration with its partners, also manufactures and could supply its high-quality and cost-effective products to licensed clients in Canada.